PMDA drug package insert
エイベリス点眼液0.002％
PMDA Prescription drug · 参天製薬株式会社 · package insert May 25, 2022
Key facts
| Brand names | エイベリス点眼液0.002％, エイベリスミニ点眼液0.002％ |
|---|---|
| Nonproprietary names | オミデネパグ イソプロピル |
| Companies | 製造販売元／参天製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 選択的EP2受容体作動薬; 緑内障・高眼圧症治療剤 |
| Therapeutic category codes | 871319 |
| YJ codes | 1319764Q1027, 1319764Q2023 |
| Approval numbers | 23000AMX00815, 30400AMX00164 |
| Package insert edition | 第4版 |
| Package insert date | May 25, 2022 |
| PMDA document key | 300237_1319764Q1027_1 |
| PMDA company code | 300237 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- 1–9 Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: